173 related articles for article (PubMed ID: 35274630)
1. Eptacog beta, a novel recombinant factor VIIa, for the treatment of hemophilia.
Watson N; Al-Samkari H
Drugs Today (Barc); 2022 Mar; 58(3):105-116. PubMed ID: 35274630
[TBL] [Abstract][Full Text] [Related]
2. Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors.
Biron-Andreani C; Schved JF
Expert Rev Hematol; 2019 Jan; 12(1):21-28. PubMed ID: 30577721
[TBL] [Abstract][Full Text] [Related]
3. Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice.
Ciolek AM; Arnall J; Moore DC; Palkimas S; Der-Nigoghossian J; Dane K
Ann Pharmacother; 2022 Jul; 56(7):831-838. PubMed ID: 34595941
[TBL] [Abstract][Full Text] [Related]
4. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
[TBL] [Abstract][Full Text] [Related]
5. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective.
Miesbach W; Carcao M; Mahlangu J; Dargaud Y; Jimenez-Yuste V; Hermans C
Haemophilia; 2024 Mar; 30(2):257-266. PubMed ID: 38317441
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors.
Pipe SW; Dunn AL; Young G
Expert Rev Hematol; 2023; 16(10):715-729. PubMed ID: 37602448
[TBL] [Abstract][Full Text] [Related]
7. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
Croom KF; McCormack PL
BioDrugs; 2008; 22(2):121-36. PubMed ID: 18345709
[TBL] [Abstract][Full Text] [Related]
8. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
Ducore J; Lawrence JB; Simpson M; Boggio L; Bellon A; Burggraaf J; Stevens J; Moerland M; Frieling J; Reijers J; Wang M
Haemophilia; 2017 Nov; 23(6):844-851. PubMed ID: 28984010
[TBL] [Abstract][Full Text] [Related]
9. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
[TBL] [Abstract][Full Text] [Related]
10. Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements.
Alexander WA; Jensen I; Hathway J; Srivastava K; Cyr P; Sidonio RF; Batt K
J Manag Care Spec Pharm; 2022 May; 28(5):518-527. PubMed ID: 35343812
[No Abstract] [Full Text] [Related]
11. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
[TBL] [Abstract][Full Text] [Related]
13. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
Wang M; Lawrence JB; Quon DV; Ducore J; Simpson ML; Boggio LN; Mitchell IS; Yuan G; Alexander WA; Schved JF
Haemophilia; 2017 Nov; 23(6):832-843. PubMed ID: 28776894
[TBL] [Abstract][Full Text] [Related]
14. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
Iorio A; Matino D; D'Amico R; Makris M
Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076
[TBL] [Abstract][Full Text] [Related]
16. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
Goldstein B; Geldziler B; Bjerre J; Seremetis S
Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
Barthels M
Thromb Res; 1999 Aug; 95(4 Suppl 1):S31-8. PubMed ID: 10499907
[TBL] [Abstract][Full Text] [Related]
18. Use of recombinant factor VIIa in hereditary bleeding disorders.
Poon MC
Curr Opin Hematol; 2001 Sep; 8(5):312-8. PubMed ID: 11604567
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.
Franchini M; Manzato F; Salvagno GL; Montagnana M; Zaffanello M; Lippi G
Semin Thromb Hemost; 2009 Nov; 35(8):814-9. PubMed ID: 20169518
[TBL] [Abstract][Full Text] [Related]
20. PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
Escobar M; Luck J; Averianov Y; Ducore J; Fernández MFL; Giermasz A; Hart DP; Journeycake J; Kessler C; Leissinger C; Mahlangu J; Martinez LV; Miesbach W; Mitha IH; Quon D; Reding MT; Schved JF; Stasyshyn O; Vilchevska KV; Wang M; Windyga J; Alexander WA; Al-Sabbagh A; Bonzo D; Mitchell IS; Wilkinson TA; Hermans C
Haemophilia; 2021 Nov; 27(6):911-920. PubMed ID: 34614267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
